Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML)

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Acute Myeloid Leukemia · TP53

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Masonic Cancer Center, Minneapolis, Minnesota, United States
Contact: Study coordinator (Joseph Norton, DO) · norto491@umn.edu · 612-626-3107

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Phase IB/II of CPX-351 for Relapse Prevention in AML

Acute Myeloid Leukemia (AML) in Remission

Abroad (travel likely)RecruitingPHASE1, PHASE2

Washington D.C., United States · Hackensack, United States

Maintenance Therapy of Hypomethylating Agent (HMA) in Favorable Risk Acute Myeloid Leukemia (AML) Patients

Acute Myeloid Leukemia

Abroad (travel likely)RecruitingPHASE2

Suzhou, China

CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant

Acute Lymphoblastic Leukemia · Acute Myeloid Leukemia · Chronic Lymphocytic Leukemia

Abroad (travel likely)RecruitingPHASE2

Duarte, United States · Atlanta, United States

A Study of Azacitidine and Venetoclax in People With Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia (AML)

Abroad (travel likely)RecruitingPHASE2

Basking Ridge, United States · Middletown, United States